1,941 results match your criteria Nature Reviews Clinical Oncology[Journal]


Therapeutic implications of germline genetic findings in cancer.

Nat Rev Clin Oncol 2019 Feb 19. Epub 2019 Feb 19.

Cancer Division, Garvan Institute of Medical Research, Sydney, Australia.

Cancer is a genetic disease. To date, translational cancer genomics has focused largely on somatic alterations, driven by the desire to identify targets for personalized therapy. However, therapeutically relevant information is also latent within the germline genome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0179-3DOI Listing
February 2019

Registration studies - when should patients be deemed ineligible for aggressive therapy?

Nat Rev Clin Oncol 2019 Feb 18. Epub 2019 Feb 18.

Division of Hematology Oncology, Oregon Health & Science University, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0180-xDOI Listing
February 2019

Challenges to curing primary brain tumours.

Nat Rev Clin Oncol 2019 Feb 7. Epub 2019 Feb 7.

CRUK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK.

Despite decades of research, brain tumours remain among the deadliest of all forms of cancer. The ability of these tumours to resist almost all conventional and novel treatments relates, in part, to the unique cell-intrinsic and microenvironmental properties of neural tissues. In an attempt to encourage progress in our understanding and ability to successfully treat patients with brain tumours, Cancer Research UK convened an international panel of clinicians and laboratory-based scientists to identify challenges that must be overcome if we are to cure all patients with a brain tumour. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-019-0177-5
Publisher Site
http://dx.doi.org/10.1038/s41571-019-0177-5DOI Listing
February 2019
6 Reads

CSF DNA provides a snapshot of the glioma genome.

Authors:
David Killock

Nat Rev Clin Oncol 2019 Mar;16(3):143

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0178-4DOI Listing

The beginning of the end for conventional RECIST - novel therapies require novel imaging approaches.

Nat Rev Clin Oncol 2019 Feb 4. Epub 2019 Feb 4.

Institute of Clinical Radiology, University Hospital Muenster, Muenster, Germany.

Owing to improvements in our understanding of the biological principles of tumour initiation and progression, a wide variety of novel targeted therapies have been developed. Developments in biomedical imaging, however, have not kept pace with these improvements and are still mainly designed to determine lesion size alone, which is reflected in the Response Evaluation Criteria in Solid Tumors (RECIST). Imaging approaches currently used for the evaluation of treatment responses in patients with solid tumours, therefore, often fail to detect successful responses to novel targeted agents and might even falsely suggest disease progression, a scenario known as pseudoprogression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0169-5DOI Listing
February 2019

Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC.

Nat Rev Clin Oncol 2019 Feb 4. Epub 2019 Feb 4.

Department of Pathology, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, UK.

The era of personalized medicine for advanced-stage non-small-cell lung cancer (NSCLC) began when biomarker-based evidence of molecular pathway and/or oncogene addiction of the tumour became mandatory for the allocation of specific targeted therapies. More recently, the immunotherapy revolution, specifically, the development of immune-checkpoint inhibitors (ICIs), has dramatically altered the NSCLC treatment landscape. Herein, we compare and contrast the clinical development of immunotherapy and oncogene-directed therapy for NSCLC, focusing on the role of predictive biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0173-9DOI Listing
February 2019
1 Read

Regulatory T cells in cancer immunosuppression - implications for anticancer therapy.

Nat Rev Clin Oncol 2019 Jan 31. Epub 2019 Jan 31.

Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Centre (EPOC), National Cancer Centre, Tokyo/Chiba, Japan.

Regulatory T (T) cells, an immunosuppressive subset of CD4 T cells characterized by the expression of the master transcription factor forkhead box protein P3 (FOXP3), are a component of the immune system with essential roles in maintaining self-tolerance. In addition, T cells can suppress anticancer immunity, thereby hindering protective immunosurveillance of neoplasia and hampering effective antitumour immune responses in tumour-bearing hosts, thus promoting tumour development and progression. Identification of the factors that are specifically expressed in T cells and/or that influence T cell homeostasis and function is important to understanding cancer pathogenesis and to identifying therapeutic targets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0175-7DOI Listing
January 2019

Real-world data: towards achieving the achievable in cancer care.

Nat Rev Clin Oncol 2019 Jan 30. Epub 2019 Jan 30.

Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Ontario, Canada.

The use of data from the real world to address clinical and policy-relevant questions that cannot be answered using data from clinical trials is garnering increased interest. Indeed, data from cancer registries and linked treatment records can provide unique insights into patients, treatments and outcomes in routine oncology practice. In this Review, we explore the quality of real-world data (RWD), provide a framework for the use of RWD and draw attention to the methodological pitfalls inherent to using RWD in studies of comparative effectiveness. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0167-7DOI Listing
January 2019

Hybrid minimally invasive surgery overtakes open surgery.

Authors:
Diana Romero

Nat Rev Clin Oncol 2019 Mar;16(3):144

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0176-6DOI Listing

Rectal cancer - not a waiting game?

Authors:
David Killock

Nat Rev Clin Oncol 2019 Jan 23. Epub 2019 Jan 23.

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0174-8DOI Listing
January 2019

Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time review.

Nat Rev Clin Oncol 2019 Mar;16(3):139-141

Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0170-zDOI Listing

CRISPR-Cas: a tool for cancer research and therapeutics.

Nat Rev Clin Oncol 2019 Jan 21. Epub 2019 Jan 21.

David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA.

In the past decade, the development of a genome-editing technology mediated by CRISPR has made genetic engineering easier than ever, both in vitro and in vivo. CRISPR systems have enabled important advances in cancer research by accelerating the development of study models or as a tool in genetic screening studies, including those aiming to discover and validate therapeutic targets. In this Review, we discuss these applications as well as new potential uses of CRISPR to assist in cancer detection or the development of anticancer therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0166-8DOI Listing
January 2019
1 Read

Desmoid tumours stalled by sorafenib.

Nat Rev Clin Oncol 2019 Jan 21. Epub 2019 Jan 21.

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0172-xDOI Listing
January 2019

FOLFIRINOX goes adjuvant.

Authors:
Diana Romero

Nat Rev Clin Oncol 2019 Mar;16(3):145

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0171-yDOI Listing

Towards risk-stratified induction regimens.

Authors:
David Killock

Nat Rev Clin Oncol 2019 Jan 15. Epub 2019 Jan 15.

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-019-0168-6
Publisher Site
http://dx.doi.org/10.1038/s41571-019-0168-6DOI Listing
January 2019
4 Reads

Truly personalized therapy - an end to the era of one size fits all.

Nat Rev Clin Oncol 2019 Feb;16(2):77-78

Breast Center, Department of Obstetrics and Gynecology and Comprehensive Cancer Center (CCCLMU), University of Munich (LMU), Munich, Germany.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-018-0165-1
Publisher Site
http://dx.doi.org/10.1038/s41571-018-0165-1DOI Listing
February 2019
6 Reads

Reshaping the critical role of surgeons in oncology research.

Nat Rev Clin Oncol 2019 Jan 7. Epub 2019 Jan 7.

North Western Hepatobiliary Unit, Aintree University Hospital, Liverpool, UK.

Surgery remains a mainstay in the treatment of most solid cancers. Surgeons have always engaged in various forms of high-quality cancer research to optimize outcomes for their patients, for example, contributing to clinical research and outcomes research as well as health education and public health policy. Over the past decade, however, concerns have been raised about a global decline in the number of surgeons performing basic science research alongside clinical activity - so-called surgeon scientists. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0149-1DOI Listing
January 2019
4 Reads

T-DM1 protects against invasive disease.

Authors:
Peter Sidaway

Nat Rev Clin Oncol 2019 Mar;16(3):145

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0164-2DOI Listing

Advances in patient care through increasingly individualized therapy.

Nat Rev Clin Oncol 2019 Feb;16(2):73-74

Division of Hematology-Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0156-2DOI Listing
February 2019

ECHELON-2 - brentuximab raises PTCL outcomes to new levels.

Authors:
David Killock

Nat Rev Clin Oncol 2019 Mar;16(3):145

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-018-0163-3
Publisher Site
http://dx.doi.org/10.1038/s41571-018-0163-3DOI Listing
March 2019
8 Reads

Two steps forward and one step back.

Nat Rev Clin Oncol 2019 Feb;16(2):69-70

Department of Medical Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-018-0154-4
Publisher Site
http://dx.doi.org/10.1038/s41571-018-0154-4DOI Listing
February 2019
3 Reads
14.180 Impact Factor

Alliance to iLLUMINATE the chemo-free sign.

Authors:
Diana Romero

Nat Rev Clin Oncol 2019 Feb;16(2):65

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0158-0DOI Listing
February 2019

Setting dictates efficacy of pembrolizumab in TNBC.

Authors:
Peter Sidaway

Nat Rev Clin Oncol 2019 Feb;16(2):66

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0157-1DOI Listing
February 2019

Apixaban reduces risk of thromboembolism.

Authors:
Peter Sidaway

Nat Rev Clin Oncol 2019 Mar;16(3):144

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-018-0162-4
Publisher Site
http://dx.doi.org/10.1038/s41571-018-0162-4DOI Listing
March 2019
1 Read

Relapsed glioblastomas respond to regorafenib.

Authors:
Peter Sidaway

Nat Rev Clin Oncol 2019 Mar;16(3):144

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0161-5DOI Listing

TIL infusions effective in HPV-associated cancers.

Authors:
Peter Sidaway

Nat Rev Clin Oncol 2019 Mar;16(3):144

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0160-6DOI Listing

MRD to help assess response in CLL.

Authors:
Diana Romero

Nat Rev Clin Oncol 2019 Feb;16(2):68

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0159-zDOI Listing
February 2019

Myeloid immune-checkpoint inhibition enters the clinical stage.

Nat Rev Clin Oncol 2018 Dec 20. Epub 2018 Dec 20.

Division of Stem Cell Transplantation and Immunotherapy, Department of Internal Medicine II, Christian-Albrechts-University, Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0155-3DOI Listing
December 2018

Advances in prediction for ovarian cancer treatment stratification.

Authors:
Amit M Oza

Nat Rev Clin Oncol 2019 Feb;16(2):75-76

Princess Margaret Cancer Centre, University Health Network and Mount Sinai Hospital University of Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0147-3DOI Listing
February 2019

Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer.

Nat Rev Clin Oncol 2018 Dec 18. Epub 2018 Dec 18.

Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, London, UK.

Women with early-stage oestrogen receptor (ER)-positive (ER) breast cancer who receive standard endocrine therapy for 5 years remain at risk of distant recurrence for at least 15 years after treatment discontinuation. The extension of the duration of adjuvant endocrine therapy to 10 years has been shown to reduce the risk of recurrence only in a subset of women and, to date, predictive biomarkers of benefit from therapy do not exist. In this Review, we briefly explore the epidemiology of late recurrence (>5 years after diagnosis) in patients with ER breast cancer. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-018-0145-5
Publisher Site
http://dx.doi.org/10.1038/s41571-018-0145-5DOI Listing
December 2018
8 Reads

mCRC: sequencing in REVERCE.

Authors:
David Killock

Nat Rev Clin Oncol 2019 Feb;16(2):67

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0152-6DOI Listing
February 2019

New high-risk molecular subtypes of DLBCL identified.

Authors:
David Killock

Nat Rev Clin Oncol 2019 Feb;16(2):68

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0153-5DOI Listing
February 2019

Reply to 'Physician burnout: let's avoid unsubstantiated claims'.

Authors:
Susana Banerjee

Nat Rev Clin Oncol 2019 Feb;16(2):137

Royal Marsden Hospital NHS Foundation Trust, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0151-7DOI Listing
February 2019

Physician burnout: let's avoid unsubstantiated claims.

Nat Rev Clin Oncol 2019 Feb;16(2):136

Institute of Work and Organizational Psychology, University of Neuchâtel, Neuchâtel, NE, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0150-8DOI Listing
February 2019

Multidisciplinary team meetings - challenges of implementation science.

Nat Rev Clin Oncol 2018 Dec 14. Epub 2018 Dec 14.

Division of Radiation Oncology, National Cancer Centre, Singapore, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0148-2DOI Listing
December 2018

Somatic and germline genomics in paediatric acute lymphoblastic leukaemia.

Nat Rev Clin Oncol 2018 Dec 13. Epub 2018 Dec 13.

Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.

Advances in genomic research and risk-directed therapy have led to improvements in the long-term survival and quality of life outcomes of patients with childhood acute lymphoblastic leukaemia (ALL). The application of next-generation sequencing technologies, especially transcriptome sequencing, has resulted in the identification of novel molecular subtypes of ALL with prognostic and therapeutic implications, as well as cooperative mutations that account for much of the heterogeneity in clinical responses observed among patients with specific ALL subtypes. In addition, germline genetic variants have been shown to influence the risk of developing ALL and/or the responses of non-malignant and leukaemia cells to therapy; shared pathways for drug activation and metabolism are implicated in treatment-related toxicity and drug sensitivity or resistance, depending on whether the genetic changes are germline, somatic or both. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-018-0136-6
Publisher Site
http://dx.doi.org/10.1038/s41571-018-0136-6DOI Listing
December 2018
10 Reads

A banner year for immunotherapy and targeted therapy.

Nat Rev Clin Oncol 2019 Feb;16(2):79-80

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0138-4DOI Listing
February 2019

Radical shifts in the first-line management of metastatic renal cell carcinoma.

Nat Rev Clin Oncol 2019 Feb;16(2):71-72

Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-018-0146-4
Publisher Site
http://dx.doi.org/10.1038/s41571-018-0146-4DOI Listing
February 2019
6 Reads

Cancer immunoediting and resistance to T cell-based immunotherapy.

Nat Rev Clin Oncol 2019 Mar;16(3):151-167

Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Queensland, Australia.

Anticancer immunotherapies involving the use of immune-checkpoint inhibitors or adoptive cellular transfer have emerged as new therapeutic pillars within oncology. These treatments function by overcoming or relieving tumour-induced immunosuppression, thereby enabling immune-mediated tumour clearance. While often more effective and better tolerated than traditional and targeted therapies, many patients have innate or acquired resistance to immunotherapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0142-8DOI Listing

Balancing opioid analgesia with the risk of nonmedical opioid use in patients with cancer.

Nat Rev Clin Oncol 2018 Dec 4. Epub 2018 Dec 4.

Department of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer, Houston, TX, USA.

The current opioid crisis has brought renewed attention and scrutiny to opioid prescriptions. When patients receiving opioid therapy for pain engage in nonmedical opioid use (NMOU) or diversion, untoward consequences can occur. New evidence suggests that patients with cancer might be at a higher risk of NMOU than was previously thought, but clinical evidence still supports the use of opioid analgesics as the gold standard to treat cancer-related pain, creating a dilemma in patient management. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-018-0143-7
Publisher Site
http://dx.doi.org/10.1038/s41571-018-0143-7DOI Listing
December 2018
8 Reads

A framework for the development of effective anti-metastatic agents.

Nat Rev Clin Oncol 2019 Mar;16(3):185-204

Commercial Partnerships, Cancer Research UK (CRUK), London, UK.

Most cancer-related deaths are a result of metastasis, and thus the importance of this process as a target of therapy cannot be understated. By asking 'how can we effectively treat cancer?', we do not capture the complexity of a disease encompassing >200 different cancer types - many consisting of multiple subtypes - with considerable intratumoural heterogeneity, which can result in variable responses to a specific therapy. Moreover, we have much less information on the pathophysiological characteristics of metastases than is available for the primary tumour. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0134-8DOI Listing
March 2019
3 Reads

Adjuvant TKIs - a long-term matter.

Authors:
Diana Romero

Nat Rev Clin Oncol 2019 Feb;16(2):67

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-018-0144-6
Publisher Site
http://dx.doi.org/10.1038/s41571-018-0144-6DOI Listing
February 2019
9 Reads

Clinical potential of mass spectrometry-based proteogenomics.

Nat Rev Clin Oncol 2018 Nov 28. Epub 2018 Nov 28.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Cancer genomics research aims to advance personalized oncology by finding and targeting specific genetic alterations associated with cancers. In genome-driven oncology, treatments are selected for individual patients on the basis of the findings of tumour genome sequencing. This personalized approach has prolonged the survival of subsets of patients with cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0135-7DOI Listing
November 2018

Integrating molecular nuclear imaging in clinical research to improve anticancer therapy.

Nat Rev Clin Oncol 2018 Nov 27. Epub 2018 Nov 27.

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.

Effective patient selection before or early during treatment is important to increasing the therapeutic benefits of anticancer treatments. This selection process is often predicated on biomarkers, predominantly biospecimen biomarkers derived from blood or tumour tissue; however, such biomarkers provide limited information about the true extent of disease or about the characteristics of different, potentially heterogeneous tumours present in an individual patient. Molecular imaging can also produce quantitative outputs; such imaging biomarkers can help to fill these knowledge gaps by providing complementary information on tumour characteristics, including heterogeneity and the microenvironment, as well as on pharmacokinetic parameters, drug-target engagement and responses to treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0123-yDOI Listing
November 2018

Neoadjuvant pembrolizumab shows promise.

Authors:
Peter Sidaway

Nat Rev Clin Oncol 2019 Jan;16(1)

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0131-yDOI Listing
January 2019

Lorlatinib effective in multiple settings.

Authors:
Peter Sidaway

Nat Rev Clin Oncol 2019 Feb;16(2):66

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0141-9DOI Listing
February 2019

Donors with CHIP are safe for allogeneic HSCT.

Authors:
Peter Sidaway

Nat Rev Clin Oncol 2019 Feb;16(2):66

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0140-xDOI Listing
February 2019

Faecal transplantation reverses colitis.

Authors:
Peter Sidaway

Nat Rev Clin Oncol 2019 Feb;16(2):66

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0139-3DOI Listing
February 2019

Second elotuzumab triplet efficacious in MM.

Authors:
David Killock

Nat Rev Clin Oncol 2019 Feb;16(2):67

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-018-0137-5
Publisher Site
http://dx.doi.org/10.1038/s41571-018-0137-5DOI Listing
February 2019
8 Reads

Less invasive is not always better.

Authors:
Peter Sidaway

Nat Rev Clin Oncol 2019 Jan;16(1)

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0133-9DOI Listing
January 2019